New investigational drug targets pancreatic cancer cells

Washington, Sep 16 (ANI): A patient at the Virginia G. Piper Cancer Center at Scottsdale Healthcare has been administered a new investigational drug designed to penetrate and attack pancreatic cancer cells.

ASG-5ME is a potent, targeted compound designed to selectively kill cancer cells, says Daniel Von Hoff, MD, a principal investigator in the Phase I clinical trial. Pancreatic cancer is a fast-growing and difficult to treat form of cancer, and is the fourth leading cause of cancer death in the United States."Our goal at the Virginia G. Piper Cancer Center is to deliver cell-killing medicine through the best possible individually targeted therapies, and ASG-5ME fits the bill," says Von Hoff.

The new investigational compound uses a monoclonal antibody against a target which is found in more than 90 percent of pancreatic cancer patients. The monoclonal antibody delivers a highly potent molecule called monomethyl auristatin E (MMAE) to selectively kill the pancreatic cancer cells.

"It is a precision approach that is designed to avoid non-targeted cells, increasing antitumor activity in preclinical models and potentially reducing the toxic effects of traditional chemotherapy" says Dr. Von Hoff. Researchers are studying the drug to evaluate its safety and tolerability and identify the maximum tolerated dose.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare was the first to offer patient access to ASG-5ME. Researchers hope to enroll up to 50 patients in clinical trials of the drug in multiple centers across the U.S. (ANI)

Please Wait while comments are loading...